Amlitelimab for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Nov 2021: Trial registered, NCT05131477
  2. 13 Dec 2021: Trial started, NCT05131477

The trials

NCT05131477: Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

State
Completed
Phase
Phase 2
People
390 taking part
Started
13 Dec 2021
Primary completion
26 Apr 2023
Arms
250mg (500mg Loading Dose) KY1005, 250mg (No Loading Dose) KY1005, 125mg KY1005, 62.5mg KY1005
Results
Posted on the registry
Papers
doi:10.1007/s13555-025-01609-6, doi:10.1016/j.jaci.2024.10.031, doi:10.1111/jdv.20877
  1. 23 Nov 2021: Trial registered
  2. 13 Dec 2021: Trial started
  3. 21 Feb 2024: Trial completed
  4. 3 Jul 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.